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Introduction
Colorectal cancer (CRC) is the third most prevalent cancer in developed countries and a serious social and economic burden (Torre et al., 2015; Paolillo et al., 2016) . According to the Cancer Statistics of China in 2015, CRC is the fifth and fourth most commonly diagnosed cancer in men and women, respectively, in the Chinese population (Chen et al., 2016b) . Undoubtedly, suppressing metastasis is a highly and urgently desirable approach for treating patients with CRC. Metastatic progression is regulated by changes in the micro-environment, such as angiogenesis, inflammation and cancerized stroma and intravasation, which involve epithelial-mesenchymal transition (EMT) (Gupta and Massague, 2006) . EMT in tumour progression allows a polarized epithelial cell to acquire a mesenchymal cell phenotype (Kalluri and Weinberg, 2009) . It also facilitates intravasation of tumour cells into blood or lymph vessels and subsequent formation of distant metastasis (Radisky, 2005) . EMT has also been proposed to be involved in the pathogenesis of CRC (Zhu et al., 2013) .
Endostatin, a 20 kDa peptide fragment generated from collagen XVIII, is known to be an inhibitor of both angiogenesis (O'Reilly et al., 1997) and endothelial cell proliferation and/or migration (Dkhissi et al., 2003) . This peptide has the potential to suppress colon tumourigenesis (Sudhakar et al., 2003) and cancer metastasis. However, the full-length endostatin protein cannot be produced as a therapeutic for colon cancer because of certain unfavourable issues, such as difficulties in its isolation, purification and delivery (Harris, 1998; Marshall, 2002; Folkman, 2006) . It has been reported that the folded endostatin structure may influence the antitumour activity of Escherichia coli-derived insoluble endostatin (Marshall, 2002) . To solve this issue, a short peptide was synthesized. The antitumour properties of this NH 2 -terminal 27 amino-acid peptide of endostatin was found to be comparable with the full-length endostatin (Tjin Tham Sjin et al., 2005) . Likewise, we have designed a number of peptides consisting of amino acids 1-30 of endostatin with amino acids 25-31 mutated from RGIRGAD to RGDRGD (peptide 30) and investigated their ability to inhibit tumour growth (Li et al., 2011) . To produce costeffective and stable peptides, we have tested a number of different polypeptides modified from endostatin and found PEP06 to be the best with strong anti-CRC effects and a high production yield.
The RGD sequence, arginine-glycine-aspartate, is believed to be the site of cell attachment for adhesive proteins, such as cell surface proteins (Pierschbacher and Ruoslahti, 1984; Ruoslahti and Pierschbacher, 1987) . A cluster of known integrins, the heterodimeric cell surface proteins highly expressed in malignant cells, can recognize the RGD sequence within their adhesion protein ligands (Ruoslahti, 1996) . RGD has anti-metastasic properties in both in vitro and in vivo models (Saiki et al., 1990; Li et al., 2011) . When a peptide/protein is conjugated or fused with RGD, it acquires a new feature and can be targeted to tumour tissues (Rubtsov et al., 2016) . Therefore, we attempted to fuse RGD sequences with the active fragments of endostatin to form a new clinical-stage polypeptide drug that possesses stronger antitumour effects.
MiRNAs can act as either carcinogenic genes or tumour suppressor genes to facilitate or retard EMT; they are critically involved in tumour metastasis and have the potential to act as biomarkers for cancer diagnosis, treatment and prognosis (Tang et al., 2016) . The EMT-regulating miRNAs can also interact with some key transcription factors to regulate the function of epithelial or mesenchymal cells (Bracken et al., 2015) . For instance, miR-146b-5p has been shown to induce EMT via targeting ZNRF3 in thyroid cancer (Deng et al., 2015) . In colon cancer, aberrant regulation of a subset of miRNAs has been demonstrated to be involved in cancer progression (Valeri et al., 2014; Cantini et al., 2015) . Yet the potential pathophysiological role of miR-146b-5p in EMT of CRC has not been investigated.
In this study, we examined the antitumour effects of an endostatin-RGDRGD 30-amino-acid fusion polypeptide (PEP06) both in vitro and in vivo. We found that PEP06 attenuated CRC metastasis without affecting cell viability or generating cytotoxicity. We further determined that the molecular mechanism of its antitumour activity involves downregulating miR-146b-5p to derepress its target gene Smad4.
Methods

Cell lines, culture conditions and reagents
The human SW620 colorectal adenocarcinoma [American Type Culture Collection (ATCC) ® CCL-227™], HCT116
colorectal carcinoma (ATCC CCL-247™), LOVO colorectal adenocarcinoma (ATCC CCL-229™) and HUVEC (ATCC PCS-100-010™) cell lines were purchased from the ATCC (Manassas, VA, USA). With the exception of SW620, the cell lines were maintained in RPMI-1640 medium (SH30027.01; Hyclone, Logan, UT, USA), supplemented with 10% FBS and 1% antibiotic-antimycotic solution (Beyotime, Shanghai, China) at 37°C in 5% CO 2 . The SW620 cells were cultured in L-15 medium (SH30525.01; Hyclone) containing 2 mM glutamine, 10% FBS and 1% antibiotic-antimycotic solution in free gas exchange with atmospheric air. PEP06 (Arg-Gly-Asp-Arg-Gly-Asp-Met-His-Ser-His-ArgAsp-Phe-Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-ProLeu-Ser-Gly-Gly-Met) was dissolved in glucose, which was synthesized by Chengdu Shengnuo Tech Co., Ltd. (Chengdu, China). The cyclic RGD peptide cilengitide was also dissolved in glucose (Aladdin, Shanghai, China). An artificial 24 amino acid with the RGD motif deleted was synthesized by ChinaPeptides (Shanghai, China) and dissolved in glucose. These three solutions were all filtered through a microporous membrane (0.22 μm; Millipore, Billerica, MA, USA). A similar positive peptide drug ENDOSTAR ® was purchased from Simcere Pharmaceutical Group (Shandong, China). The oligonucleotide fragments were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China), including miR-146b-5p mimic, a negative control (NC) duplex, miR146b-5p inhibitor and miRNA inhibitor NC. The sequences are listed in Supporting Information Table S1 . ) for 24 h were analysed for apoptosis with TUNEL assay by using the In Situ Cell Death Detection Kit (cat. no. 11684817910; Roche, Mannheim, Germany) according to the manufacturer's instructions. Cells were fixed with 4% paraformaldehyde, infused with 0.1% Triton X-100 and incubated with TUNEL Reaction Mixture for 1 h at 37°C in the dark. After DAPI counterstain for 10 min at room temperature, cells were photographed with a fluorescence microscope. The assay was repeated in five times (Zeiss, Jena, Germany).
Cell viability by MTTassay
Cell-cycle analysis
After treatment with PEP06 for 24 h, the cells were harvested and stained with the Cycletest Plus DNA Reagent Kit (BD Biosciences, Franklin Lakes, NJ, USA) following the instructions of the manufacturer. Flow cytometry (LSRFortessa; BD Biosciences, San Jose, CA, USA) was used to determine the changes in cell cycle. The results were analysed using FlowJo 7.6.1 (BD Biosciences, Franklin Lakes, NJ, USA).
Tube formation
The tube formation assay was conducted as described previously (Kim et al., 2013) . Briefly, 24-well plates were coated with growth factor-reduced Matrigel (250 μL per well; Corning, New York, NY, USA). HUVECs pretreated with 200 μg·mL À1 were plated in 200 μL EBM-2 medium at a cell density of 5 × 104 cells/well, and incubated with 5% CO 2 at 37°C for 12 h to allowed for tube formation. HUVECs were harvested, and 1.5 × 10 5 cells were resuspended in EBM-2 medium containing 0.5% FBS. Cells were plated onto the Matrigel layer, then PEP06 was added at a final concentration of 200 μg·mL À1 .
After 6 h incubation at 37°C, images showing the formation of capillary-like structures were obtained with an inverted microscope (Olympus, Tokyo, Japan) at 100 × magnification. Tubular structures were assessed by measuring the number of branches using Image-Pro Plus software. Tube formation was quantified by counting the number of branching nodes and the tube length in three randomly selected fields five times.
Wound-healing assay
HCT116 and SW620 cells were seeded onto a six-well plate at a density of 5 × 10 5 cells mL À1 until they reached full confluence. The cells were cultured for 24 h in the presence of varying concentrations of PEP06. Then they were starved overnight and scratched by using a 200 μL pipette tube the next day. Glucose solution (5%) was used as a negative control. In another experiment, SW620 cells transfected with miR-146b-5p lentiviral expression vector and control vector were also seeded. Photographs were captured by a digital single lens reflex camera (Canon, Tokyo, Japan) at 0 and 24 h respectively. Other transwell assays using miR146b-5p lentiviral expression vector or the control lentiviral vector transfected SW620 cells were carried out using the same procedure. A total of 600 μL medium containing 10% FBS was added to the lower chambers. After incubation for 24 h, non-migrating and non-invading cells were gently removed by a cotton swab. The cells were then fixed with methanol for 30 min and stained with 0.1% crystal violet for another 20 min. The area of dyed pores was then calculated under a microscope at a magnification of ×400. Five views were selected randomly for photography and analysis. Each measurement was repeated five times.
Western blot analysis
Whole-cell lysates were extracted by RIPA (Beyotime) with protease (Roche, Mannheim, Germany 
MiRNA microarray analysis
The miRNA profiling analysis was conducted by Shanghai KangCheng Biosciences using the Exiqon miRCURY™ LNA Array system, which contained 2043 capture probes covering all human miRNAs (Exiqon, Vedbaek, Denmark). PEP06 was added to SW620 or HCT116 cells for 24 h, and the addition of 5% glucose served as a control. Total RNA was extracted from pretreated cells with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and miRNeasy mini kit (Qiagen, Shenzhen, China). After quality control, the miRCURY™ Hy3™/Hy5™ Power labelling kit (Exiqon) was used according to the manufacturer's guideline for miRNA labelling. Afterwards, the Hy3™-labelled samples were hybridized on the miRCURY™ LNA Array (v.19.0; Exiqon) according to the array manual. Then images of the chip were scanned using an Axon GenePix 4000B microarray scanner (Axon Instruments, Foster City, CA, USA). The spot densityderived raw data were extracted from non-coding RNA profiling by array software and deposited on the Gene Expression Omnibus database (accession number GSE111493). MiRNAs with intensities >50 were used to calculate the normalization reference. Expression data were analysed using the median normalization, and then differentially expressed miRNAs between the two groups were identified through fold change (FDNAs w and P-value, P < 0.05).
Quantitative real-time PCR
Total RNA was extracted from pretreated cells with TRIzol reagent (Invitrogen). The cDNAs were produced from the RNA samples with Reverse Transcription Kit (Toyobo, Shanghai, China) and miRNA specific Bulge-loop™ miRNA RT primers (Invitrogen). Human U6 snRNA was used as an endogenous control for data normalization. Real-time PCR was performed on the ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using SYBR Green I RealTime PCR kit (Roche Diagnostics, Mannheim, Germany). Relative miRNA expression was determined using the Ct method. All experiments were performed at least five times. The primer sequences are listed in Supporting Information Table S1 . Response unit values at each concentration were measured during the equilibration phase for steady-state affinity fittings using either Biacore T200 evaluation software 2.0.3. Kinetic rate constants were determined by fitting globally to the 1:1 Langmuir (one-to-one binding) model embedded in the Biacore T200 evaluation software v3.0.
Surface plasmon resonance
Transfection of miRNA
MiR-146b-5p mimic (miR-146b), miR-146b-5p inhibitor (AMO-146b) and miR-146b-5p NC were synthesized by Shanghai GenePharma Co., Ltd. SW620 cells were plated onto a six-well plate at 5 × 10 4 cells in 2 mL culture medium overnight until the desired density of 50-70% confluency was achieved. Then they were transfected with the mimic, NC or the mixture of mimic and inhibitor by using XtremeGENE siRNA Transfection Reagent (Roche) following the manufacturer's instructions.
Establishment of SW620 cells stably overexpressing miR-146b-5p
Stable transfectants overexpressing miR-146b-5p were generated by lentiviral transduction using LV-3 (pGLVH1/ GFP + Puro) plasmid harbouring miR-146b-5p-coding sequence. MiR-146b-5p-expressing lentiviruses and its negative control (miR-Ctl) containing the GFP were packaged by Shanghai GenePharma Co., Ltd. SW620 cells (5 × 10 4 ) were seeded in six-well plates and cultured to about 90% confluence. The cells were transfected with the miR146b-5p or negative control lentiviral plasmids using X-tremeGENE siRNA Transfection Reagent and incubated in fresh medium containing 1.0 μg·mL À1 puromycin (SigmaAldrich) 6 h post-transfection. The presence of GFP was detected through the fluorescence microscopy at 24 h after infection. Drug-resistant cell colonies were individually picked up using tips, seeded into a 24-well plate, cultured and passed with selection pressure. The expression level of miR-146b-5p was determined with quantitative real-time PCR (qRT-PCR).
Smad4 overexpression using lentiviral expression system
Lentiviral vectors of Smad4 and a negative control were purchased from GeneChem (Shanghai, China). Stably expressed miR-146b-5p (miR-146b-OE) and the matched control lines (miR-Ctl) SW620 cells (6 × 10 5 ) were plated in the six-well plates and cultured to about 90% confluence. Cells were then infected by adding the Smad4 or negative control lentiviral vectors in 2 mL of L-15 medium at multiplicity of infection of 35 plaque-forming units per cell, followed by addition of 10 times volume of virus enhanced infection solution. Mock infection (Ctl) was performed by treating cells with vehicle (medium) only. After an 8 h incubation, the medium was replaced with 2 mL of fresh L-15 medium containing 10% FBS and 1% antibiotic-antimycotic. Cells were trypsinized after 72 h and prepared for Western blot analysis.
In vivo animal experiments
Our protocol for animal use was approved by the Institution Animal Care and Use Committee of Harbin Medical University, and all animal experiments were carried out according to the Guide for the Care and Use of Laboratory Animals, and in strict accordance with the People's Republic of China Legislation Regarding the Use and Care of Laboratory Animals. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Postsurgical residual tumour xenograft models and antitumour effect assay
Adult female athymic BALB/c nude mice (15-20 g), 4 weeksold, were purchased from Nanjing Biomedical Research Institute of University [certificate no. SCXK (Su) 2015-0001]. The animals were housed in a controlled environment at 23 ± 2°C under a 12 h dark/light cycle with free access to irradiated food and sterile water. We established a murine model with a postsurgical residual tumour to mimic the recurrence of solid tumour as described previously . The LOVO tumour cells (over 5 × 10 7 mL À1 ) were harvested and washed with sodium chloride. Cell suspension of 1 × 10 6 in 0.2 mL was injected s.c. into the right axillary of mice to establish the traditional tumour xenograft nude mouse model. When the tumours reached an average volume of 1000-1500 mm 3 , they were removed from the mice aseptically and diced into small cubes (2.0 × 2.0 × 2.0 mm). These tumour chunks were injected s.c. into the right axillary of the mice to establish a murine model with a postsurgical residual tumour. When the tumours had reached an average volume of 300-350 mm 3 , the mice were anaesthetized by an i.v. injection of 1.2% avertin (2,2,2-tribromoethanol) solution (0.2 mL per 10 g mouse weight). A small incision was made to remove tumour tissues around the tumour edge aseptically, leaving a residual tumour volume of 60-100 mm 3 .
Twenty-four hours after the surgery, the mice were sorted into three groups (n = 8) on the basis of tumour volume. Body weight was measured twice a week. The mice in the PEP06 treatment groups were administered PEP06 by i. and then imaged using IVIS Spectrum CT platform (PerkinElmer, Waltham, MA, USA). Living image 4.3.1 software was used for data analysis (PerkinElmer). The mice were weighed every 5 days. After the experiments had been terminated, the lungs were removed to calculate the lung/body weight ratio. During the course of the treatment, the percentage of tumour growth was determined using the formula: %tumour growth = (total flux of photons of the control group À total flux of photons of PEP06 groups) total flux of photons of the control group × 100%. To determine the pulmonary metastasis of the CRC tumour model and the efficacy of PEP06, 5 min after injection of CLY tumour cells, mice (n = 30) were randomly divided into three groups, and one of them was used as the normal group with regular food and drink. According to bioluminescence imaging (BLI) signals, the remaining mice (n = 20) were randomly divided into two groups: control (n = 10) and PEP06 (n = 10). The animals received an i.v. injection of 5% glucose solution (control) or 20 mg·kg À1 PEP06 once a day for 45 days. The mice were killed on day 45, and the main internal organs (lung, brain, colon, spleen, kidney, heart, stomach and small intestine) were harvested for ex vivo bioluminescent imaging and macroscopic weighting.
In another colon cancer metastasis xenograft model used to evaluate the effects of miR-146b-5p, SW620-miR-Ctl or SW620-miR-146b cells (2 × 10 6 ) were suspended in 200 μL PBS and then injected into the tail vein of the 8-week-old BALB/c nude mice (n = 8 for each group). Forty days postimplantation, the animals were killed, and the tumours, livers and lungs were dissected, fixed in 4% formalin overnight and embedded in paraffin. To evaluate metastasis, serial sections from the lungs with primary tumours were stained with haematoxylin-eosin staining.
Tissue microarray construction and immunohistochemistry
Tissue microarray (TMA) construction was performed on 38 tumour samples from the postsurgical residual tumour xenograft nude mice. Nine tissue samples were obtained from the control group and 29 from the high-dosage groups (20 mg·kg À1 ). Two cores of formalin-fixed, paraffinembedded tumour tissues were taken, and the diameters of the punched cores ranged from 1.5 to 2.0 mm. TMA sections (4 mm) from 76 sites were obtained using standard techniques for immunohistochemistry (IHC) or in situ hybridization. Slides were scanned by an AperioScanScope ® slide scanner (Leica Biosystems Inc., Buffalo Grove, IL, USA). For IHC, heat-induced epitope retrieval was performed by use of Citrate Antigen Retrieval solution (Solarbio, Beijing, China) for 40 min for vimentin, or by EDTA Antigen Retrieval solution (ZSGB-Bio, Beijing, China) for E-cadherin and MMP9. The tissue preparations were incubated with the primary antibodies for E-cadherin (1:500; #14472S; Cell Signaling Technology, Danvers, MA, USA), vimentin (1:250; HPA001762; Sigma-Aldrich) or MMP9 (1:200; ab76003; Abcam) at 4°C overnight, followed by incubation with the secondary antibody EnVision™+/HRP mouse (rabbit) polymer (Dako, Glostrup, Denmark) at room temperature for 30 min. Secondary antibody detection was performed by using the SIGMAFAST™ 3,3 0 -diaminobenzidine tablets (DAB Peroxidase Substrate Tablet Set) (D4168; Sigma-Aldrich). Slides were counterstained with haematoxylin for 2 min following colour separation by 1% acetic acid for 30 s. The reaction products were visualized by the EnVision Detection System (Dako).
In situ hybridization
The slides were deparaffinized in xylene and then pre-digested with 15 μg·mL À1 proteinase K (for 5-15 min at 37°C). Subsequently, they were prehybridized with 5 0 -DIG and 3 0 -DIG labelled miRCURY LNA™ Detection probe (has-miR-146b-5p, 5 0 -AGCCTATGGAATTCAGTTCTCA-3 0 ; Exiqon) in hybridization buffer at 50°C for 1 h. Then the slides were washed thoroughly in SCC buffers, followed by incubation with anti-DIG-AP Fab fragments. Finally, the slides were counterstained with nuclear fast red and mounted using ProLong Gold solution (Invitrogen).
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . In general, statistical comparisons between two groups were conducted with Student's t-test, and between multiple groups were determined by one-way ANOVA with Dunnett's post hoc test. A probability value of 0.05 was considered to be significant. Results are expressed as mean ± SEM.
For miRNA microarray analysis, results are presented as mean ± SD. Data were analysed by one-way ANOVA, Student's unpaired two-tailed t-test or by two-way ANOVA among multiple groups at a point in time with Bonferroni correction.
Survival curves were plotted by use of the Kaplan-Meier technique and compared with the log-rank test. Results are expressed as the mean of at least five or more determinations. Statistical analysis was performed by using GraphPad Software 5.0 (GraphPad Software, San Diego, CA, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017 /18 (Alexander et al., 2017a .
Results
PEP06 possesses similar activity to endostatin
It is well known that angiogenesis is vital event for tumour growth and metastasis (Folkman, 1971) . PEP06 was designed based on the effective motif of endostatin, and as such, it should possess similar anti-angiogenic activity to the latter. HUVECs can spontaneously form a three-dimensional tubular capillary-like network on Matrigel culture. To examine the effect of PEP06 on tubule formation of HUVECs, we performed a tube formation assay in the presence of PEP06 at a concentration of 200 μg·mL À1 and compared its effects with that of the RGD-sequences-deleted PEP06 (namely, 24 amino acid or 24aa in this study). PEP06 produced greater inhibition of tube formation than 24aa (Supporting Information Figure S1C, D) . Numerous studies have demonstrated that the expression level of VEGF is critical for tumour angiogenesis (Goel and Mercurio, 2013) . Therefore, we next examined whether PEP06 affects VEGF expression. As shown in Supporting Information Figure S1E , F, PEP06 significantly inhibited VEGF expression in HUVECs. Compared with PEP06, 24aa also down-regulated VEGF expression but with much a weaker effect. These results suggest that PEP06 and 24aa both regulated angiogenesis to exert their antitumour activities in vitro. We then further examined the inhibitory effect of PEP06 on tumour angiogenesis using a postoperative recurrent tumour model depicted in Figure 6 . Immunohistochemical staining of VEGF with the tumour sections from PEP06-treated mice showed significantly decreased microvessel density compared with the vehicle group (Supporting Information Figure S1G , H), indicating that PEP06 inhibited tumour growth by inhibiting angiogenesis in xenograft mice.
PEP06 suppresses CRC via inhibiting metastasis
Impairing cell viability due to decreased cell proliferation, increased cellular apoptosis and G 2 /M cell-cycle arrest are the most common mechanisms for anticancer drugs. As the first step towards understanding the actions of PEP06 in CRC, the effects of PEP06 on cell proliferation and/or death were assessed by measuring the viability of colon cancer cells and HUVECs using the MTT assay. As shown in Figure 1 and Supporting Information Figure S1A , there were no significant differences in the number of viable cells among the PEP06-treated group, the vehicle-treated ( Figure S1A , B). Subsequently, a TUNEL assay was performed to detect apoptotic cells. The TUNEL positive cells (red fluorescence) did not significantly decrease after PEP06 treatment as compared with the control SW620 cells (Supporting Information Figure  S2A ). Furthermore, we examined whether PEP06 can block cell-cycle progression in SW620 cells. Flow cytometry analysis showed a similar percentage of cell-cycle arrest at the G 2 / M-phase in PEP06-treated SW620 cells to that in control cells (Supporting Information Figure S2B ). The results indicate that PEP06 does not produce any net effects on cell proliferation, apoptosis or cell-cycle arrest at the G 2 /M phase at the concentrations tested in our models. It is possible that PEP06 suppresses CRC by an alternative mechanism; specifically, PEP06 might act on metastasis.
To examine this point, we investigated the effects of PEP06 on the migration of CRC cells by wound-healing and transwell migration assays. As illustrated in Figure 2A , B, wound-healing experiments revealed that PEP06 treatments (50, 100 and 200 μg·mL À1 ) for 24 h substantially inhibited the migration of both SW620 and HCT116 cells (Figure 2A , B, E). Similar results were observed with the transwell migration assay ( Figure 2C, D, F) . In particular, PEP06 at a concentration of 200 μg·mL À1 led to 87.2 and 92.1% inhibition of migration in SW620 and HCT116 cells, respectively.
PEP06 inhibits EMT in CRC cells
EMT is a critical process for aggressive metastatic dissemination of carcinomas (Polyak and Weinberg, 2009 ), which undergoes multiple and dynamic transitional states from epithelial to mesenchymal phenotypes. Decreases in mesenchymal markers N-cadherin and vimentin and/or increases in epithelial markers E-cadherin and α-catenin indicate dampening of EMT, and vice versa (Nieto et al., 2016) . We explored whether EMT plays a role in mediating the antimetastasis property of PEP06 by measuring the expression changes of these biomarkers using Western blot analysis. As depicted in Figure 3A , B, PEP06 significantly inhibited EMT at all three concentrations tested, as indicated by the down-
Figure 1
Lack of effects of PEP06 on the viability of SW620, HCT116 and LOVO cells. Relative or % cell viability was determined by MTT assay with the OD values from the PEP06 groups normalized to those from the control groups. The measurements were taken 24 or 48 h after PEP06 treatment. The data show the lack of significant effect of varying concentrations of PEP06 (50, 100 and 200 μg·mL À1 ) on viability in SW620, HCT116 and LOVO cells at 24 h (A-C) and 48 h (D-F) after treatment. Glucose (GS) solution was used as a vehicle control and 5-FU (12.5 μg·mL À1 ) as a positive control. Averaged data (mean ± SEM, n = 5) of OD in 570 nm. * P < 0.05 by one-way ANOVA; Dunnett's test for comparison with Ctl.
PEP06, tumourigenesis and colon cancer regulation of N-cadherin and vimentin expression and concomitant up-regulation of E-cadherin and α-cadherin expression in SW620 and HCT116 cells. It was noted that the effects were not concentration-dependent ( Figure 3D , E). Consistently, immunofluorescent staining demonstrated that PEP06 (200 μg·mL À1 ) treatment for 24 h resulted in a significant decrease in vimentin expression and an increase in Ecadherin expression relative to control as well ( Figure 3C ).
PEP06 decreases the expression of miR-146b-5p by direct binding to integrin αvβ3
To elaborate the potential mechanisms by which PEP06 inhibits metastasis of CRC cells and EMT, we set up the following experiments looking at the effects of PEP06 on miRNAs.
We first employed miRNA microarray analysis to identify the differentially expressed miRNAs in both SW620 cells and HCT116 cells pretreated with PEP06 at a concentration of 200 μg·mL À1 for 24 h. According to the criteria with a cut-off fold change >1.5 and P-value ≤0.05, we found miR146b-5p to be a differentially expressed miRNA ( Figure 4A ). qRT-PCR confirmed that the expression level of miR-146b-5p was considerably reduced in both SW620 and HCT116 cells exposed to PEP06 of varying concentrations (50, 100 and 200 μg·mL À1 ; Figure 4B , C). The data are summarized in Table 1 . We then examined the effects of another two endostatinderived short peptides Endostar and the 24aa. The results showed that neither Endostar nor 24aa inhibited the expression of miR-146b-5p. By comparison, cilengitide, a cyclic RGD peptide-targeting integrin αvβ3 and αvβ5, significantly reduced the expression of miR-146b-5p ( Figure 4D , E). SPR revealed that the biotinylated PEP06 had an appreciable binding affinity for integrin αvβ3. Moreover, PEP06 exhibited a high affinity for integrin αvβ3, which was dose-dependent, with the mean K d value of 5.07 ± 0.39 nM ( Figure 4F ), while 24aa failed to bind to integrin αvβ3 ( Figure 4G ). These results suggest that the regulation of miR-146b-5p by PEP06 might be due to the direct binding of PEP06 to integrin αvβ3.
MiR-146b-5p mediates the inhibitory effect of PEP06 on EMT in CRC cells
Since miR-146b-5p has been shown to be involved in promoting metastasis of CRC (Zhu et al., 2017) , we determined whether or not miR-146b-5p can regulate the EMT in CRC cells. We overexpressed miR-146b-5p in SW620 with lentivirus infection and plasmid vector transfection. Successful introduction of miR-146b-5p into the cells was confirmed by qRT-PCR (Supporting Information Figure S3A ). Normal SW620 cells and empty lentivirus (miR-Ctl) were used as negative controls. Transwell migration assay demonstrated that miR-146b-5p overexpression increased the number of SW620 cells passing through the membrane ( Figure 5A, B) . Meanwhile, miR-146b-OE significantly accelerated the migration of these cells ( Figure 5D , E). To further understand the impact of miR-146b-5p on the CRC metastasis, SW620 cells with or without stable expression of miR-146b were inoculated into the tail vein of nude mice. Overexpression of miR-146b-5p markedly increased the visible pulmonary metastasis compared with the negative control (Supporting Information Figure S3B ) and decreased the expression levels of epithelial markers while increasing the levels of mesenchymal markers ( Figure 5E , F and Supporting Information Figure S3D ). Immunofluorescent staining showed that miR-146b-5p overexpression decreased the expression of the epithelial marker E-cadherin and increased the expression of the mesenchymal marker vimentin in SW620 cells ( Figure 5G ). However, the EMT-promoting effect of miR-146b-5p was partially reversed by co-transfection with on the protein expression of EMT marker genes in SW620 and HCT116 cells observed by immunofluorescent staining. Blue: DAPI; green: Ecadherin; and red: vimentin. Scale bar: 20 μm. (D, E) PEP06 increased E-cadherin and α-cantenin protein levels and decreased N-cadherin and vimentin protein levels compared with the negative controls. Averaged data (mean ± SEM) of (A, B) from five independent experiments. * P < 0.05 by one-way ANOVA, Dunnett's test: compared with Ctl. GS, glucose.
PEP06, tumourigenesis and colon cancer AMO-146b ( Figure 5E , D). Furthermore, Smad4 protein level was increased by PEP06, and miR-146b-5p reversed this alteration (Supporting Information Figure S3E , F). Since Smad4 protein has been reported to be a target for miR-146b-5p, we subsequently investigated the effects miR146b-5p on Smad4 in SW620 cells to further understand how miR-146b-5p could affect the expression of the EMT marker proteins. Indeed, compared with the control group, Smad4 protein level was decreased in SW620 cells infected or transfected with the miR-146b-5p construct, an effect that was prevented by co-transfection with AMO-146b. Concomitantly, the levels of pSmad2/3 were elevated by miR-146b-5p, which was reversed by AMO-146b ( Figure 5E , F and Supporting Information Figure S3D ). These results indicate that miR-146b-5p promoted EMT in CRC cells by downregulating the expression of Smad4. To further verify the relationship between miR-146b-5p and Smad4 in CRC, Smad4 was restored in SW620 cells stably overexpressing miR-146b-5p (Supporting Information Figure S3G , H).
PEP06 suppresses CRC tumour growth by inhibiting miR-146b-5p in vivo
It is well known that surgical resection accelerates the growth of residual tumours. We next evaluated the antitumour activity of PEP06 in a postoperative recurrent tumour model and its effects on the expression of miR-146b-5p. The primary colon tumours were surgically removed leaving a portion of the tumours, 60 mm 3 , to mimic the postoperative recurrence in the clinic. The average tumour volume, tumour weight and body weights were measured twice a week. Following a single dosage of 10 or 20 mg·kg À1 (body weight) by injection through the tail vein, PEP06, but not 5% glucose, effectively suppressed the growth of residual tumours after surgical resection, with 20 mg·kg À1 showing greater antitumour activity (tumour weight inhibitory rate % = 68.2% and tumour volume inhibitory rate % = 73.3%) than 10 mg·kg
À1
(tumour weight inhibitory rate % = 44.7% and tumour volume inhibitory rate % = 64.1%; Figure 6A , B). The antitumour activities of PEP06 are summarized in Table 2 . The body weight of nude mice remained stable after PEP06 treatment. Accordingly the antitumour activity of PEP06 was verified in xenograft mice. TMA was performed using the samples from the high-dosage group. The in situ hybridization results demonstrated that the expression of miR-146b-5p was downregulated by PEP06 (20 mg·mL À1 ; Figure 6C ). In a follow-up IHC study, the epithelial marker E-cadherin was found to be up-regulated while the mesenchymal marker N-cadherin down-regulated by PEP06 (200 mg·kg À1 ). MMPs, especially MMP2 and MMP9, have been demonstrated to promote tumour progression and are implicated in EMT (Kessenbrock et al., 2010; Vinnakota et al., 2017) . In this study, as demonstrated by IHC, the degradation of MMP9 was inhibited by PEP06 in the tumours from the high-dosage group ( Figure 6D ).
PEP06 inhibits metastatic capacity in vivo
To demonstrate the efficacy of PEP06 (20 mg·kg À1 ) at inhibiting the metastasis of colon cancer in vivo, BLI was used to monitor and compare metastatic tumour growth of the CLY mouse model. Five minutes after i.v. injection of GFPLuc2-transfected CLY cells (1.5 × 10 6 cells per mouse), BLI images were acquired to confirm the accumulation of cells in mouse lungs ( Figure 7A, B) . The mice were divided into two groups (n = 10) with equal mean BLI signal intensities. During the first 7 days, most of these signals disappeared over time in both groups compared with day 1 (data not shown), indicating that cells that failed to metastasize did not survive. However, on day 15, all control mice developed obvious bioluminescent signals in the 
Figure 5
Role of miR-146b-5p in mediating the effects of PEP06 on EMT in CRC cells. (A) MiR-146-5p and miR-control expression vectors were each transfected into SW620 cells. The transwell migration assay showing the migration ability of SW620 cells with enforced expression of miR146b-5p (miR-146b-OE) compared with the miR-Ctl. (B) Averaged data (mean ± SEM, n = 5) from the transwell migration assay showing the acceleration of migration by miR-146b-5p. * P < 0.05 by unpaired t-test, compared with miR-Ctl. (C) The wound healing assay showed that the overexpression of miR-146b (miR-146b-OE) enhanced the migratory capacity of SW620 cells compared with the negative controls (miR-Ctl) . (D) Averaged data (mean ± SEM, n = 5) from the wound-healing assay showing the acceleration of migration by miR-146b-5p. * P < 0.05 by unpaired t-test, compared with miR-Ctl. (E) Effects of ectopic expression of miR-146b-5p on the protein levels of EMT markers, Smad4 and pSmad2/3 in SW620 cells. Cells were transfected with miR-146b-5p mimic, negative control mimic or miR-146b-5p mimic together with its antisense inhibitor AMO-146b. (F) Western blot analysis showed that the level of E-cadherin, α-catenin and Smad4 was significantly decreased by the ectopic expression of miR-146b-5p, and the level of vimentin, N-cadherin and pSmad2/3 (% Smad2/3) was increased. Whereas co-transfection with miR-146b mimic and AMO-146b reversed this trend. The values of the protein band densities were normalized to those of the blank control group. Averaged values (mean ± SEM, n = 5) of Western blot band density normalized to the internal control GAPDH and to the data obtained from the Ctl groups. * P < 0.05 by one-way ANOVA, Tukey's multiple comparison test: compared with Ctl.
# P < 0.05, by one-way ANOVA, Tukey's multiple comparison test: compared with miR-146b. (G) Immunofluorescent staining of EMT marker proteins E-cadherin (green) was decreased by miR-146b mimic, and vimentin was increased (red) and DAPI was used to stain (blue) nuclei. Scale bar: 20 μm. lung. In contrast, only two PEP06-treated mice showed visible signals ( Figure 7C, D) . From days 25 to 45, PEP06 significantly attenuated the development of bioluminescent foci in the lung, showing lower BLI signals by two orders of magnitude ( Figure 7E-G) . At the end of the animal experiment (day 45), the mean in vivo BLI signal intensity of the control group was 77.5-fold higher than that on day 1, while the PEP06 groups were 2.9-fold lower ( Figure 7I , J, M). The ex vivo images also supported the finding that PEP06 inhibited lung metastasis formation ( Figure 7K , L) with inhibition amounting to 98.5%. The lung/body weight ratio is an indirect measure of pulmonary metastatic burden. Quantitative analysis of lung weight ( Figure 7O ) and lung/body weight ratio ( Figure 7P ) further confirmed the efficacy of PEP06 in inhibiting cancer metastasis. In addition, PEP06 had no obvious side effects in PEP06-treated mice, which showed stable increases in body weight during the whole course, while control mice experienced significant body weight loss in the later stage ( Figure 7N ). Of note, three mice in the control group died on day 37, and one died on day 39, while the mice in the PEP06 groups all survived. The survival time of the mice in the PEP06 groups was significantly prolonged ( Figure 7Q ). Taken together, PEP06 treatment dramatically delays and attenuates lung metastasis formation in our CLY mouse model.
Discussion
In the present study, we investigated the possible mechanisms of the antitumour activity of PEP06 in in vitro and in vivo models. Our results indicate that as an RGD-fusion endostatin polypeptide, PEP06 exerted anti-metastasis effects in CRC via inhibiting EMT as a subcellular mechanism. Mechanistically, PEP06 directly bound to integrin αvβ3 to down-regulate miR-146b-5p and its direct target gene Smad4 to elicit anti-EMT and anti-metastasis activities in colon cancer. To our knowledge, PEP06 represents the first endostatinderived RGD motif-including polypeptide that possesses strong miRNA-targeting EMT-suppressing properties, resulting in anti-angiogenic effects in colon cancer. The present study demonstrated that PEP06 had significant antitumour effects in both a CRC cell model and ex vivo xenografts from a nude mouse model. A modified endostatin with a 9-amino-acid-hanging sequence to form an additional his-tag structure acts as an angiogenesis inhibitor known as Endostar (Ling et al., 2007) , which holds potential to inhibit angiogenesis and lymphangiogenesis in CRC (Jia et al., 2012) . A synthetic recombinant endostatin-derived 27 peptide also elicits strong antitumour, anti-migration and antipermeability activities in lung cancer (Tjin Tham Sjin et al., 2005) . Interestingly, PEP06 did not affect cell viability (Figure 1) , which was consistent with Endostar exerting small inhibitory effects on the growth of human oesophageal squamous cell carcinoma (Chen et al., 2016a) . As an RGD motif was introduced, we assumed that the effect of PEP06 was not simply due to direct tumour cell killing but additional mechanisms are involved, such as anti-metastasis. The PEP06 dosage used in this study was within the effective range reported by Wu et al. (2008) .
Table 2
Antitumour activity of PEP06 on postsurgical residual tumour xenografts of human LOVO colon cancer in nude mice The significance of differences (vs. control) was determined by one-way ANOVA with t-test. QD, every day. *P < 0.05 (n = 8, x ± s)
Figure 7
PEP06 inhibits lung metastasis in CRC and increases mouse survival. (A-I) Bioluminescence (BLI) of tumour progression in mice after injection of CLY cells pretreated with glucose (GS) and PEP06 at day 1 (A), day 15 (C), day 25 (E), day 35 (G) and day 45 (I). The statistical charts of the BLI signal intensities at day 1 (B), day 15 (D), day 25 (F), day 35 (H) and day 45 (J). Measurements were automatically generated as an integrated flux of photons (photons s À1 ; p·s À1 ) by the LivingImage ® processing software. The images framed by a yellow box show the dead mice. Three mice died at day 37, and one died at day 39. During follow-up, the lung metastasis of CLY cells was significantly hampered in the PEP06-treated group when compared with that in the Ctl group (GS). Other than the modifications mentioned above, some studies aimed to assemble endostatin with some functional components. In this study, we inserted a consecutive RGD motif into the basic fragment of endostatin. Integrins are key regulators in communication between cells and their micro-environment (Nieberler et al., 2017) . Certain integrins (namely, αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1 and α8β1) can recognize the RGD motif and affect cell adhesion with strikingly distinct profiles (Nieberler et al., 2017) . The importance of αvβ3 integrin in mediating colon cancer growth and metastasis has been demonstrated previously (Reinmuth et al., 2003) , as the RGD motif can also be used for tumour treatment (Wang et al., 2013) , and several RGD-modified endostatins have been synthesized in other laboratories. Li et al. (2011) showed that the RGD-modified endostatin polypeptide 30 produces strong antitumour activities in vitro possibly through the αvβ3 integrin pathway. In another study, RGD-P125A-endostatin-Fc fusion proteins were constructed to increase the half-life of endostatin and to enhance its antiangiogenic and antitumour activities (Jing et al., 2011) . The RGD sequence has also been added to the Nor C-terminus of EDSM (a synthetic polypeptide contains the amino acids 6-48 of endostatin) to enhance the interaction of endostatin with integrin αvβ3, thereby improving its antiangiogenic activity (Pu et al., 2012 ). An introduction of one RGD motif could be a drug carrier specifically targeting tumour angiogenesis (Mitra et al., 2005; Pu et al., 2012) . RGD sequences alone are also able to inhibit cancer metastasis in vitro and in vivo (Saiki et al., 1990; Li et al., 2011) by crosstalking with the integrin superfamily that mediates cell migration and invasion. Metastasis is a bottleneck in cancer therapy including colon cancer (Ganguly et al., 2013) , a process that is associated with EMT (Nieberler et al., 2017) . EMT has been implicated in the processes of tumour metastasizing to distant areas and in the acquisition of therapeutic resistance (Polyak and Weinberg, 2009 ). Shah et al. (2012) reported that a pituitary tumour-transforming gene has effects on cell migration and the induction of EMT through the regulation of the integrin αvβ3-FAK signalling pathway in lung cancer. The RGD motif also contributes to TGFβ1-induced EMT suppression in renal cell carcinoma (Feldkoren et al., 2017) . In agreement with these published studies, the present study showed that PEP06 inhibited CRC metastasis in a dosedependent manner and significantly restricted the migration of CRC cells (Figure 2 ). During the follow-up in the postoperative residual tumour models , we found the weight of mice was kept within a relatively stable range during the course of PEP06 treatment, indicating the toxicity of PEP06 is mild (Figure 6 ). In the present study, PEP06 increased the expression of mesenchymal markers and concomitantly decreased the expression of epithelial markers, which is consistent with the view that EMT is critical to the metastasis of colon cancers (Chen et al., 2016a) . Moreover, our xenograft model of LOVO cells clearly demonstrated that PEP06 markedly decreased CRC pulmonary metastasis. Collectively, we have demonstrated that PEP06 can inhibit CRC metastasis by, at least in part, suppressing EMT both in vitro and in vivo.
To our knowledge, there has not been any RGD-modified drug applied in the clinic until now. The tumour-homing peptide RGD selectively targets both tumour endothelial cells and tumour cells (Zitzmann et al., 2002) by specifically binding to αvβ3 integrin, which is commonly overexpressed in many cancer cells and can increase tumour targeting efficiency (Park et al., 2016) . And integrins (such as αvβ3) recognize RGD sequences in ECM proteins. It has been reported that the amino acids 60-70 of endostatin including surface-exposed arginine residues can interact with integrins (Wickstrom et al., 2004) . We also demonstrated that the RGD motif included in PEP06 possessed αvβ3 integrin-binding affinity and, thereby, leads to changes in the expression of miR-146b-5p ( Figure 4F ). Although previous studies have demonstrated that the RGD motif can recognize integrins, we are the first to verify the direct binding of an RGD-modified peptide with integrin. Drugs designed based on the RGD structure may also provide a new treatment for targeting tumours with minimal toxicity (Rubtsov et al., 2016) . This assumption was validated by the MTT assay in vitro (Figure 1 ) and postsurgical residual tumour xenografts animal models in vivo ( Figure 6B ). Possibly due to the introduction of RGD, PEP06 could effectively target tumour cells and inhibit the growth of colon cancer. Our results support the notion that RGD-modified endostatin might open up a new and more effective regimen for cancer therapy.
Our study further revealed that miR-146b-5p is a key regulator for the underlying mechanisms of anti-EMTmediated metastasis of PEP06 as demonstrated by the significant down-regulation of miR-146b-5p after PEP06 treatment ( Figure 4A, B) . This regulation of PEP06 tightly relied on the existence of the RGD motif as well as the expression of integrin αvβ3 in CRC cells, as the treatment with Endostar or 24aa showed no effects on the level of miR146b-5p, while the RGD peptides cilengitide inhibited miR-146b-5p to a greater extent relative to the peptides without an RGD motif (Figure 4 ). This suggests that RGD sequences mediate the effect of PEP06 on miR-146b-5p; however, the detailed mechanisms by which the RGD sequence down-regulates miR-146b-5p are still not clear. A number of studies have shown that miR-146b-5p plays an important role in the initiation and development of colon cancer (Kanaan et al., 2012; Ranjha et al., 2015) through either regulating pyruvate dehydrogenase B (Zhu et al., 2017) or inducing EMT (Deng et al., 2015) . In our study, miR146b-5p significantly promoted EMT phenotypes in cells, which is consistent with the research of Zhu et al. (2017) , indicating that at least in CRC, miR-146b-5p has an oncogenic role. Furthermore, our findings suggest Smad4 as a molecular basis for the modulating effect of miR-146b-5p on EMT, as revealed by Geraldo's group (Geraldo et al., 2011) . Smad4 associates with the phosphorylated receptorregulated Smads (pSmads) and mediates TGFβ signal transduction, a pathway that plays a key role in regulating EMT of cancer cells (Bardeesy et al., 2006) . As demonstrated by the elevated level of pSamd2/3 after miR-146b-5p treatment, Smad4 increased the responsiveness of the TGFβ pathway ( Figure 5 and Supporting Information Figure S3 ).
In conclusion, this study elucidated a mechanism by which PEP06 exerts its anti-metastasis effects in CRC; it appears to inhibit EMT through down-regulating miR-146b-5p, revealing an important role of miR-146b-5p in the regulation of Smad4 and thereby TGFβ. A schematic diagram is provided in Figure 8 for explaining our findings. PEP06 also appeared to have an ameliorative effect, combating the recurrence of post-resection colon cancer. We speculate that PEP06 could improve the life quality of late-stage CRC patients with few and tolerable side effects.
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